CA2505949A1 - Process for designing inhibitors of influenza virus non-structural protein 1 - Google Patents

Process for designing inhibitors of influenza virus non-structural protein 1 Download PDF

Info

Publication number
CA2505949A1
CA2505949A1 CA002505949A CA2505949A CA2505949A1 CA 2505949 A1 CA2505949 A1 CA 2505949A1 CA 002505949 A CA002505949 A CA 002505949A CA 2505949 A CA2505949 A CA 2505949A CA 2505949 A1 CA2505949 A1 CA 2505949A1
Authority
CA
Canada
Prior art keywords
dsrna
protein
influenza virus
ns1a
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002505949A
Other languages
English (en)
French (fr)
Inventor
Gaetano T. Montelione
Robert M. Krug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers, The State University of New Jersey
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2505949A1 publication Critical patent/CA2505949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002505949A 2002-11-13 2003-11-13 Process for designing inhibitors of influenza virus non-structural protein 1 Abandoned CA2505949A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42566102P 2002-11-13 2002-11-13
US60/425,661 2002-11-13
US47745303P 2003-06-10 2003-06-10
US60/477,453 2003-06-10
PCT/US2003/036292 WO2004043404A2 (en) 2002-11-13 2003-11-13 Process for designing inhibitors of influenza virus non-structural protein 1

Publications (1)

Publication Number Publication Date
CA2505949A1 true CA2505949A1 (en) 2004-05-27

Family

ID=32314599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002505949A Abandoned CA2505949A1 (en) 2002-11-13 2003-11-13 Process for designing inhibitors of influenza virus non-structural protein 1

Country Status (5)

Country Link
US (2) US20080234175A1 (enExample)
JP (1) JP2006506101A (enExample)
AU (1) AU2003290842A1 (enExample)
CA (1) CA2505949A1 (enExample)
WO (1) WO2004043404A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288544B6 (sk) * 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
EP1855713B1 (en) * 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
EP1948796A1 (en) * 2005-11-07 2008-07-30 Dow Gloval Technologies Inc. Process for the preparation of nucleic acid duplexes
US9119810B2 (en) 2005-11-18 2015-09-01 Rutgers, The State University Of New Jersey Compositions and vaccines against influenza A and influenza B infections
US7601490B2 (en) 2005-12-02 2009-10-13 Board Of Regents, The University Of Texas System Development of influenza A antivirals
US7709190B2 (en) 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
CN102002489B (zh) * 2009-09-02 2013-06-12 中国科学院微生物研究所 抑制H1N1型流感病毒增殖的microRNA及其应用
WO2011147199A1 (en) * 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
KR101471245B1 (ko) * 2012-05-31 2014-12-10 충북대학교 산학협력단 Ａ형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
US20240398941A1 (en) * 2021-10-06 2024-12-05 Seqirus Inc. Lipid nanoparticle comprising a nucleic acid-binding protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
IL134862A0 (en) * 1997-09-12 2001-05-20 Genelabs Tech Inc dsRNA/dsRNA-BINDING PROTEIN METHODS AND COMPOSITIONS

Also Published As

Publication number Publication date
AU2003290842A1 (en) 2004-06-03
US20080234175A1 (en) 2008-09-25
JP2006506101A (ja) 2006-02-23
WO2004043404A2 (en) 2004-05-27
AU2003290842A8 (en) 2004-06-03
US20100081126A1 (en) 2010-04-01
WO2004043404A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
US20100081126A1 (en) Process for designing inhibitors of influenza virus structural protein-1
AU2004215133B2 (en) Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
Serrano et al. Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus
Chien et al. Biophysical characterization of the complex between double-stranded RNA and the N-terminal domain of the NS1 protein from influenza A virus: evidence for a novel RNA-binding mode
Lin et al. Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target
Zhao et al. Influenza virus infection causes global RNAPII termination defects
Houben et al. Interaction of the C-terminal domains of sendai virus N and P proteins: comparison of polymerase-nucleocapsid interactions within the paramyxovirus family
Trempe et al. NMR solution structure of an oligonucleotide hairpin with a 2 ‘F-ana/RNA stem: Implications for RNase H specificity toward DNA/RNA hybrid duplexes
Keane et al. Solution structure of mouse hepatitis virus (MHV) nsp3a and determinants of the interaction with MHV nucleocapsid (N) protein
CA3020012C (en) Aptamers, nucleic acid molecules, polynucleotides, synthetic antibodies compositions for detecting prrs viruses and treating prrs virus infection
Li et al. SRSF5‐mediated alternative splicing of M gene is essential for influenza A virus replication: a host‐directed target against influenza virus
Wang et al. Guanidine modifications enhance the anti‐herpes simplex virus activity of (E, E)‐4, 6‐bis (styryl)‐pyrimidine derivatives in vitro and in vivo
Borin et al. Murine norovirus protein NS1/2 aspartate to glutamate mutation, sufficient for persistence, reorients side chain of surface exposed tryptophan within a novel structured domain
Diefenbacher et al. Interactions between influenza A virus nucleoprotein and gene segment untranslated regions facilitate selective modulation of viral gene expression
Lan et al. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library
EP2379715B1 (en) Polypeptide fragments comprising endonuclease activity and their use
Yang et al. SARS‐CoV‐2 NSP12 utilizes various host splicing factors for replication and splicing regulation
Johnson et al. NMR structure of the SARS-CoV nonstructural protein 7 in solution at pH 6.5
Woltz et al. The NS1 protein of influenza B virus binds 5’-triphosphorylated dsRNA to suppress RIG-I activation and the host antiviral response
Woltz et al. The NS1 protein of influenza B virus binds 5’-triphosphorylated dsRNA to suppress RIG-I activation and the antiviral innate immune response
Wang et al. Structure of Crimean–Congo haemorrhagic fever virus RNA polymerase
WO2014121299A1 (en) Nmr assay to screen protein-protein interaction inhibitors
Ni et al. Structural basis of the C-terminal domain of SARS-CoV-2 N protein in complex with GMP reveals critical residues for RNA interaction
Yin Structural studies of human interferon-stimulated gene 15 protein product and its binding partner, the N-terminal 103 residues of non-structural protein 1 from influenza B virus
Woltz Hybrid Structural Biology Studies Reveal a Novel Mechanism by Which Influenza B NS1 Protein Suppresses Host Innate Immune Response

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170517